Kojin Therapeutics
Cambridge
About Kojin Therapeutics
Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables the development of selective therapies for a broad range of hard-to-treat diseases. The company’s investors include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, and the Dana-Farber Cancer Institute venture firm, Binney Street Capital.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $60.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2021)
- Website: kojintx.com
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/kojin-therapeutics-2263 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.